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Abstract Vascular endothelial growth factor (VEGF) stimu-
lates endothelial cell (EC) migration. The protein kinase Akt
activates the endothelial NO synthase (eNOS) by phosphoryla-
tion of Ser-1177. Therefore, we investigated the contribution of
Akt-mediated eNOS phosphorylation to VEGF-induced EC
migration. Inhibition of NO synthase or overexpression of a
dominant negative Akt abrogated VEGF-induced cell migration.
In contrast, overexpression of constitutively active Akt was
sufficient to induce cell migration. Moreover, transfection of an
Akt site phospho-mimetic eNOS (S1177D) potently stimulated
EC migration, whereas a non-phosphorylatable mutant (S1177A)
inhibited VEGF-induced EC migration. Our data indicate that
eNOS activation via phosphorylation of Ser-1177 by Akt is
necessary and sufficient for VEGF-mediated EC migra-
tion. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Vascular endothelial growth factor (VEGF) is a potent
soluble growth factor, which plays a key role in regulating
normal and abnormal angiogenesis [1]. VEGF acts via stim-
ulation of the VEGF receptors 1 (Flt-1) and 2 (Flk-1/KDR),
which are both expressed on endothelial cells (EC) [2]. VEGF
not only promotes EC proliferation and migration [3], but
also prevents apoptosis of endothelial cells thereby improving
EC survival [4].
Several reports have implicated NO in the angiogenic re-
sponse to VEGF. VEGF has been shown to up-regulate NO
synthesis in endothelial cells [3,5,6]. In vitro, VEGF-induced
EC proliferation requires NO production [7,8]. More recently,
the chemotactic e¡ect of VEGF on endothelial cells was
shown to depend on endothelial NO synthesis [9]. A key
role for NO as a downstream mediator of VEGF is further
implied by the ¢nding that mice lacking endothelial NO syn-
thase (eNOS) are resistant to VEGF-induced angiogenesis
[10]. The molecular mechanism underlying the requirement
of NO to mediate the angiogenic e¡ects of VEGF on EC is
unknown.
Several recent studies documented the involvement of the
phosphatidylinositol 3-kinase (PI3K)/Akt pathway to contrib-
ute to the cytoprotection of EC by VEGF [4,11]. Likewise, the
PI3K/Akt pathway was shown to directly activate eNOS by
phosphorylation at Ser-1177 rendering enzyme activity calci-
um-independent [12,13]. Therefore, we investigated whether
Akt-dependent phosphorylation of eNOS mediates the e¡ects
of VEGF on EC migration using a ‘scratched wound assay’,
which resembles re-endothelialization processes.
2. Materials and methods
2.1. Cell culture
Human umbilical venous endothelial cells (HUVEC) (Clonetics,
Solingen, Germany) were cultured in EGM-1 medium supplemented
with hydrocortisone (1 Wg/ml), bovine brain extract (3 Wg/ml), genta-
micin (50 Wg/ml), amphotericin B (50 Wg/ml), epidermal growth factor
(10 Wg/ml), and 10% fetal calf serum (FCS) until the third passage.
2.2. Cell migration
For detection of cell migration, in vitro ‘scratch’ wounds were cre-
ated by scraping cell monolayers with a sterile disposable rubber
policeman [14]. Therefore, HUVEC were grown on 6 cm wells, which
were previously labeled with a traced line. After injury, the cells were
gently washed with medium and stimulated with recombinant VEGF
and the respective inhibitors. EC migration from the edge of the
injured monolayer was quanti¢ed by measuring the distance between
the wound edges before and after injury using a computer-assisted
microscope (Zeiss, Jena, Germany) at ¢ve distinct positions (every
5 mm).
2.3. Detection of proliferating cells
HUVEC were incubated with 10 WM bromodeoxyuridine (BrdU)
for 1 h, and incorporated BrdU was detected by staining with a FITC-
linked anti-BrdU antibody (50 Wg/ml in phosphate-bu¡ered saline
(PBS)/0.1% bovine serum albumin, Boehringer Mannheim, Germany)
followed by counterstaining with 4P,6-diamidinophenylindole (DAPI)
(1 Wg/ml). The absolute numbers of BrdU-positive cells were counted
at ¢ve di¡erent positions out of 500 cells.
2.4. Plasmids and transfection
The plasmid encoding the human eNOS was a gift from Dr. Na-
kane and was subcloned as described previously [12]. The putative
Akt sites were changed by site-directed mutagenesis [12]. The plasmids
encoding Akt were cloned in pcDNA3.1 vector as described [15].
Clones were transfected in HUVEC (3.5U105cells/6 cm well) with
3 Wg plasmids and 25 Wl Superfect (Qiagen, Hilden, Germany) as
described previously [12]. After the transfection procedure, culture
medium was removed and 3 ml medium was added for 3 h before
‘scratch’ wounds were created. Transfection e⁄ciency was about 50%
as determined using green £uorescent protein and was maximal from
18 to 36 h. Expression of the eNOS constructs was determined by
Western blot analysis as described previously [12]. Immunohistochem-
istry against the myc tag of the constructs was performed after ¢xa-
tion of the cells with paraformaldehyde using anti-myc antibodies
(1:70 in PBS/5% FCS, Santa Cruz) as primary and anti-mouse-anti-
bodies linked to FITC (1:20 in PBS/5% FCS, Dako) as secondary
antibodies.
2.5. Statistics
Data are expressed as mean þ S.E.M. from at least three indepen-
dent experiments. Statistical analysis was performed by t-test for the
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comparison of two groups and for multiple groups by one-way AN-
OVA analysis (LSD test).
3. Results
3.1. VEGF-induced EC migration depends on PI3K/Akt and
NO synthase
Incubation of HUVEC with VEGF induced a dose-depen-
dent increase in EC migration with a maximal e¡ect at
10 ng/ml as detected with the ‘scratched wound assay’ (Fig.
1A). VEGF is known to stimulate EC proliferation [2]. There-
fore, we tested whether the enhanced closure of the wound
might involve a proliferative e¡ect. In general, a very low
proliferation rate of about 3% was detected in re-endothelial-
ized parts of the culture dish in time course experiments (12,
24, 36, and 48 h) (Fig. 1B) con¢rming previous publications
demonstrating that the scratched wound assay mainly deter-
mines migration of cells [14]. The absolute number of prolif-
erating EC in re-endothelialized areas of the wound was even
lower compared to control cells or to the EC growing outside
the wound (33 þ 7%) (Fig. 1C). However, although the abso-
lute number of proliferating EC in the re-endothelialized area
was very low, VEGF stimulation slightly enhanced the pro-
liferation index of EC in this area at all time points with
maximal e¡ects at 48 h (control: 2.8 þ 0.02%; VEGF: 4.2 þ
0.06% BrdU-positive cells).
Next, we tested the involvement of PI3K/Akt and NO in
EC migration. Inhibition of NOS by NG-mono-methyl-L-argi-
nine (LNMA) completely prevented VEGF-induced migration
(Fig. 2A), demonstrating that VEGF-induced EC migration
depends on endogenous NO synthesis. The pharmacological
PI3K inhibitors Ly294002 and wortmannin suppressed
VEGF-induced migration even below unstimulated controls
(Fig. 2A). Previous studies excluded toxic e¡ects of the inhib-
itors [15]. Overexpression of a dominant negative Akt mutant
prevented VEGF-induced EC migration (Fig. 2B). The in-
volvement of Akt was further demonstrated by investigating
the e¡ect of a constitutive active Akt (T308D/S473D). Over-
expression of the active Akt kinase was su⁄cient to stimulate
EC migration even in the absence of VEGF (Fig. 3A). Immu-
nohistochemical analysis using an antibody against the myc
tag of the active Akt illustrates the distribution of the Akt-
expressing cells (Fig. 3B). Finally, LNMA was shown to pre-
vent Akt-induced EC migration (Fig. 3A), demonstrating that
Akt acts via NO.
3.2. Ser-1177 of eNOS is required for VEGF-mediated EC
migration
Having demonstrated that VEGF-induced EC migration
requires activation of Akt, we analyzed the speci¢c role of
phosphorylation of eNOS at Ser-1177, which serves as accep-
tor amino acid for Akt-mediated eNOS phosphorylation
Fig. 1. Detection of VEGF-induced EC migration and proliferation. A: HUVEC were scratched and stimulated with the indicated concentra-
tions of VEGF. After 48 h, cell migration was detected as described in Section 2. Data are mean þ S.E.M., n = 4 with *P6 0.05 versus control.
B,C: Detection of proliferating endothelial cells. HUVEC were scratched and stimulated with VEGF (10 ng/ml). At the indicated time points,
proliferating EC were detected by anti-BrdU staining (see Section 2). Nuclei were stained with DAPI. B: Magni¢cation: 11U. C: Overview
with 22U magni¢cation after treatment with VEGF for 36 h. The red line denotes the edge of the scratched wound. Representative experiments
are shown (n = 3).
FEBS 23781 14-7-00 Cyaan Magenta Geel Zwart
S. Dimmeler et al./FEBS Letters 477 (2000) 258^262 259
[12,13]. For that purpose, we overexpressed a phospho-mim-
etic eNOS construct, where Ser-1177 was replaced by aspar-
tate (S1177D). Expression of the phospho-mimetic eNOS con-
struct signi¢cantly stimulated EC migration in the absence of
VEGF (Fig. 4A,B). Incubation with VEGF did not further
stimulate cell migration in cells expressing the phospho-mim-
etic S1177D eNOS mutant (Fig. 4A,B). Inhibition of NOS by
LNMA completely blocked EC migration induced by eNOS
S1177D, demonstrating the NO dependence of the e¡ect (Fig.
4A). In contrast, EC migration in eNOS wild type transfected
cells was stimulated by VEGF to a similar extent compared to
cells transfected with the control vector (Fig. 4A). To ¢nally
test whether eNOS phosphorylation at Ser-1177 is necessary
for VEGF-induced cell migration, Ser-1177 was replaced by
alanine (S1177A) to prevent Akt-mediated activation of the
eNOS. Overexpression of eNOS S1177A abrogated VEGF-
induced EC migration (Fig. 4A,B). As mentioned above,
VEGF slightly increased EC proliferation in the re-endothe-
lialized area of the wound. Therefore, we investigated the
e¡ect of the phospho-mimetic and non-phosphorylatable
eNOS constructs on the proliferation of EC. However, trans-
Fig. 2. VEGF-induced EC migration depends on PI3K and NO. A:
HUVEC were scratched and incubated with LNMA (1 mM),
Ly294002 (Ly, 10 WM), wortmannin (W, 20 nM) and VEGF (10 ng/
ml). Cell migration was determined after 48 h (n = 9, *P6 0.01 ver-
sus control, #P6 0.01 versus VEGF). Representative pictures are
shown on the right. B: HUVEC were transfected with an empty
control vector (pcDNA3.1), dominant negative Akt (Aktmt) or ac-
tive Akt (T308D/S473D) and cell migration was stimulated with
VEGF (10 ng/ml) for 48 h. Data are mean þ S.E.M., n = 6,
*P6 0.01 versus vector+VEGF, #P6 0.05 versus vector, **P6 0.01
versus active Akt.
6
Fig. 3. Akt stimulates endothelial cell migration. A: HUVEC were transfected with vector or active Akt (T308D/S473D) and stimulated with
VEGF (10 ng/ml) and LNMA (1 mM). After 48 h EC migration was determined. Data are mean þ S.D., n = 4. B: Immunohistochemical stain-
ing against the myc tag of the active Akt (T308D/S473D) in transfected cells after stimulation with VEGF for 36 h. Magni¢cation: 14U. A
representative image is shown.
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fection with the S1177D or S1177A construct revealed no
e¡ect on the number of BrdU-positive cells in the re-endothe-
lialized areas of the wound (vector: 2.8 þ 0.03%; S1177D:
2.75 þ 0.05%, S1177A: 2.73 þ 0.1% BrdU-positive EC). Equal
expression of the eNOS constructs was demonstrated by
Western blot analysis (Fig. 4C).
4. Discussion
Previous studies suggested that activation of the protein
kinase Akt by VEGF or shear stress inhibits EC apoptosis
and, therefore, promotes EC survival [4,11,15]. The results
of the present study now extend these ¢ndings by demonstrat-
ing that VEGF-induced EC migration also depends on the
PI3K/Akt pathway. Thereby, Akt-mediated eNOS activation
mediates VEGF-stimulated EC migration. Phosphorylation of
eNOS at Ser-1177 is not only necessary, but also su⁄cient for
EC migration.
It is well established that endothelium-derived NO plays an
important role in VEGF-induced angiogenesis in vitro and in
vivo [7,9,10]. Initial studies suggested that VEGF stimulation
leads to a rapid increase in intracellular calcium [16], which
then triggers calcium/calmodulin-dependent NO synthesis.
The calcium-dependent activation of NO synthase, however,
lasts only for a very short time period, approximately 5 min.
Although VEGF was shown to up-regulate eNOS mRNA and
protein levels [17], activation of eNOS is still required to en-
hance the enzymatic activity. The data of the present study
provide a molecular explanation for the NO dependence of
EC migration. Phosphorylation of eNOS at Ser-1177, which
has been shown to serve as the acceptor amino acid of Akt-
mediated phosphorylation [12,13], stimulates EC migration
even in the absence of VEGF. Interestingly, the non-phos-
phorylatable eNOS completely abrogates the e¡ects of
VEGF on EC migration. The complete inhibition of VEGF-
induced cell migration by the non-phosphorylatable eNOS
construct is surprising, bearing in mind that the transfection
e⁄ciency is about 50%. However, control experiments con-
¢rmed equal expression levels of the transfected proteins
and further excluded potential toxic e¡ects of the construct
(data not shown). The inhibitory e¡ect might be explained by
the fact that the S1177A construct acts as a dominant negative
mutant as suggested by our previous experiments [12]. The
inhibition of NO synthesis, which prevents cell migration of
the transfected cells, may in£uence the migration of the over-
all cell population possibly by impairment of the cell^cell
interaction required for migration. It is well established that
endothelial cells are linked to each other by adherens-type
junctions, called cadherins. These cadherins transfer intracel-
lular signals and play a major role in cell migration [18]. Thus,
inhibition of migration of an individual cell is always accom-
panied by an inhibitory signal on the neighboring cells. Taken
together, these data demonstrate that stimulation of EC mi-
gration by VEGF requires the phosphorylation of eNOS at
Ser-1177 via Akt.
It is well established that VEGF also promotes EC prolif-
eration. However, assessing the proliferation rate in the re-
endothelialized areas of the wound revealed a very low num-
ber of proliferating endothelial cells, which indicates that the
closure of the wound is mainly due to migration of EC into
the wound. Importantly, the proliferative response is not af-
fected by transfection with the non-phosphorylatable eNOS
constructs. Therefore, one may speculate that eNOS phos-
phorylation and activation predominantly regulates cell mi-
gration but not proliferation. This observation may closely
correspond to recently published data demonstrating that an-
giopoietin 1, which promotes cell survival and cell migration
but does not directly stimulate cell proliferation, activates the
Akt pathway [19]. Therefore, stimulation of cell proliferation
may need additional pathways activated by VEGF but not by
angiopoietin 1, which are independent of Akt-dependent NOS
phosphorylation [20].
Stimulation of angiogenesis may be a potential therapeutic
strategy for angiogenesis and postnatal neovascularization in
patients with ischemic heart disease [1]. Gene transfer with
naked DNA encoding VEGF or recombinant VEGF has
been used as a therapeutic approach [1]. However, this treat-
ment depends on the functional integrity of the signal trans-
duction pathways including the expression of the VEGF re-
ceptors and the activation of eNOS, which is often impaired
in patients with atherosclerotic risk factors [21]. Since the
phospho-mimetic eNOS construct enhances EC migration to
a similar extent as VEGF but acts downstream of VEGF,
gene therapy with this construct might be a novel therapeutic
approach to induce angiogenesis or re-endothelialization.
Fig. 4. Phosphorylation of Ser-1177 is essential for VEGF-induced
EC migration. A,B: HUVEC were transfected with di¡erent eNOS
constructs (wild type eNOS: wt; phospho-mimetic eNOS: S1177D;
non-phosphorylatable eNOS: S1177A) or control vector. Cell migra-
tion was stimulated by VEGF (10 ng/ml) and determined after 48 h.
NO synthase was inhibited by LNMA (1 mM). Data are mean þ
S.E.M., n = 6 with *P6 0.01 versus vector, #P6 0.05 versus
wt+VEGF, P6 0.05 versus wt and **P6 0.05 versus S1177D.
Representative pictures are shown in B. C: Expression of the eNOS
constructs. After transfection protein was isolated and a Western
blot against eNOS was performed. A representative blot is shown
(n = 7).
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